Protein detail
ADA2C
Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR)
Protein symbol ADA2C | UniProt ID | EVMP score 0.25 |
Frequency 2 | Transmembrane count 7 | Protein classification FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins |
Basic Information
Protein Names
Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR)
Protein Class
FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins
Protein Function
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Transmembrane
49..74; Helical; Name=1; 88..110; Helical; Name=2; 122..147; Helical; Name=3; 168..187; Helical; Name=4; 209..231; Helical; Name=5; 384..408; Helical; Name=6; 417..440; Helical; Name=7
Transmembrane Count
7
Ensembl
Entrez Gene Symbol
Gene Synonym
ADRA2L2ADRA2RL2ADRARL2
Gene Description
Adrenoceptor alpha 2C
Chromosome
4
Position
3766348-3768526
Frequency
2
EVMP Score
0.25
Fluorescence & Localization
Tissue Specificbone marrowCell SpecificMonocyte progenitors
Function & Pathway
Protein Function
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Cellular Component
Molecular Function
Biological Process
KEGG
Reactome
- R-hsa-400042 adrenaline noradrenaline inhibits insulin secretion
- R-hsa-390696 adrenoceptors
- R-hsa-375280 amine ligand binding receptors
- R-hsa-373076 class a 1 rhodopsin like receptors
- R-hsa-500792 gpcr ligand binding
- R-hsa-418594 g alpha i signalling events
- R-hsa-418597 g alpha z signalling events
- R-hsa-109582 hemostasis
- R-hsa-163685 integration of energy metabolism
- R-hsa-76002 platelet activation signaling and aggregation
- R-hsa-76009 platelet aggregation plug formation
- R-hsa-422356 regulation of insulin secretion
- R-hsa-372790 signaling by gpcr
- R-hsa-5683826 surfactant metabolism
Canonical Pathways
- M33 Pid glypican 1pathway
- M252 Pid il8 cxcr1 pathway
- M76 Pid p38 alpha beta pathway
Mediation Categories
Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
46 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | CellPhoneDB | No | Yes | No | Yes | No |
| receptor | receptor | HPMR | No | Yes | No | Yes | No |
| receptor | receptor | CellChatDB | No | Yes | No | Yes | No |
| receptor | receptor | Surfaceome | No | Yes | No | Yes | No |
| gpcr | receptor | DGIdb | No | Yes | No | Yes | No |
| gpcr | receptor | Almen2009 | No | Yes | No | Yes | No |
| rhodopsin | receptor | Almen2009 | No | Yes | No | Yes | No |
| gpcr | receptor | UniProt_keyword | No | Yes | No | Yes | No |
| seven_transmembrane_7tm | receptor | HPMR | No | Yes | No | Yes | No |
| 7tm_a | receptor | HPMR | No | Yes | No | Yes | No |
Page 1 of 5Next
Regulatory Interaction Network
4 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| ADA2C | P18825 | GNAZ | P19086 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| ADA2C | P18825 | GNAI3 | P08754 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| ADA2C | P18825 | GNAI1 | P63096 | Yes | Yes | No | SIGNOR | SIGNOR:31160049 |
| ADA2C | P18825 | GNAO | P09471 | Yes | Yes | No | HPRDSIGNOR | HPRD:1349607SIGNOR:31160049 |
Protein Complex Composition
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Mass spectrometry | 0 |
Sequence, Structure & Domains
Sequences
Length
462
Mass
49,522
Sequence
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGFLIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFGQVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISAVISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLRTRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGALRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
3D Structural Models
Helix
48..78; 80..82; 85..87; 88..103; 105..114; 120..154; 156..160; 165..183; 208..218; 220..239; 372..408; 409..412; 416..428; 429..431; 433..440; 442..452
3D Structure
X-ray crystallography (1)
Domain & Motif Annotations
Compositional Bias
294..308; Basic residues; 311..325; Gly residues
Region
246..347; Disordered
Protein Families
- G-protein coupled receptor 1 family
- Adrenergic receptor subfamily
- ADRA2C sub-subfamily
Sequence Similarities
Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRA2C sub-subfamily.
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases
Acute diabete complicationAlzheimer diseaseAsthmaChronic arterial occlusive diseaseChronic kidney diseaseChronic painCoronavirus infectionDementiaDepressionDissociative neurological symptom disorderGeneral pain disorderGenetic cardiac arrhythmiaGlaucomaHeart failureHerpes simplex infectionHypertensionHypotensionNon-specific cutaneous vascular symptonObesityOrgasmic dysfunctionPainPeptic ulcerPost-traumatic stress disorderProstate diseaseSexual dysfunctionSubstance abuseUnspecific body region injuryUnspecific substance harmful effectVasomotor/allergic rhinitis
Biomarker
Discontinued in Phase 2; Phase 2; Terminated; Phase 3; Preclinical; Investigative; Discontinued in Phase 3; Approved; Discontinued in Preregistration; Phase 4
Drug Targets
FDA approved drug targets
Drugs
TETRAHYDROZOLINE HYDROCHLORIDENAPHAZOLINE HYDROCHLORIDEVASOACTIVE INTESTINAL PEPTIDEAMOSULALOLAJMALICINELOFEXIDINENULLPROPYLHEXEDRINETETRAHYDROZOLINEEPINEPHRINE BITARTRATELOFEXIDINE HYDROCHLORIDEFIPAMEZOLEMEDETOMIDINEMIRTAZAPINENOREPINEPHRINESENREBOTASEOLANZAPINERILMENIDINEESMIRTAZAPINE MALEATECLONIDINE HYDROCHLORIDEAPRACLONIDINE HYDROCHLORIDEIDAZOXANDOPAMINEMOXISYLYTEXYLOMETAZOLINEDEBRISOQUINYOHIMBINEFENOLDOPAM MESYLATEDIHYDROERGOCRISTINETIZANIDINE HYDROCHLORIDEBETA-ALANINERAUWOLFIA SERPENTINA (USP)FADOLMIDINELEVONORDEFRINERGOLOID MESYLATES, USPMETHAMPHETAMINEEPHEDRINEERGOTAMINE TARTRATEGUANFACINE HYDROCHLORIDEEPHEDRINE HYDROCHLORIDEBUCINDOLOL HYDROCHLORIDEBETHANIDINEMETHYLDOPA ANHYDROUSISOPROTERENOLBRIMONIDINEORM-12741AMEZINIUMPHENTOLAMINE MESYLATEASENAPINEEPINEPHRINELABETALOL HYDROCHLORIDEFADOLMIDINE HYDROCHLORIDECELIPROLOLDEXMEDETOMIDINE HYDROCHLORIDEPHENOXYBENZAMINE HYDROCHLORIDEMOXONIDINEGUANABENZ ACETATENOREPINEPHRINE BITARTRATEILOPERIDONEDROXIDOPAOPC-28326MEPHENTERMINE SULFATETETRASULMETHYLDOPATE HYDROCHLORIDEOXYMETAZOLINE HYDROCHLORIDEDIPIVEFRIN HYDROCHLORIDEMETOPROLOLIDAZOXAN HYDROCHLORIDETOLAZOLINE HYDROCHLORIDEHYDROXYAMPHETAMINE HYDROBROMIDELURASIDONE HYDROCHLORIDECYCLOBENZAPRINE
Antibody